Furthermore, a preclinical study showed that BRAF inhibition leads to upregulation of a variety of receptor tyrosine kinases in CRC cell lines, including EGFR, HER2 and HER3 [45]. This evidence concerns the gene NTRK1 and colorectal carcinoma.